article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Ailing Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 344
article thumbnail

DEA Promises Progress on Federal Cultivation Applications, But Provides No Timetable for Action

NORML

The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.

DEA 169
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. After receiving a petition three years prior, the DEA finally answered with action, making plans to deschedule [18F]FP-CIT , a controlled substance derived from cocaine. .”

DEA 98
article thumbnail

Rod Kight and Shane Pennington Discuss DEA Lawsuit (Video)

Cannabis Law Report

Rod Kight and Shane Pennington discuss the DEA lawsuit about hemp extracts. As many readers of this blog know, the… Read More.

DEA 81
article thumbnail

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Cannabis Law Report

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT.

DEA 96
article thumbnail

Doctor Sues DEA for Right to Give Psilocybin to Dying Patients

Project CBD

Psilocybin, the psychedelic mushroom extract, has been fast-tracked by the FDA to treat depression, but doctors still can’t use it in their practice.

DEA 150
article thumbnail

‘The Doors are Wide Open’: Denver Cannabis Company Gets DEA Approval To Expand Alzheimer’s Research

Cannabis Law Report

“We’re interested in how cannabinoids affect the nervous system, the brain, and in in particular, we’re very interested in Alzheimer’s disease,” said Dr. Tyrell Towle, director of chemistry and extraction at MedPharm. The new DEA research license will now change that.

DEA 105